Sulimax

Quick links to important sections

Sulimax

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulimax

Quick Facts

Property Description
Active Ingredient Mesalazine (INN) / 5-aminosalicylic acid (5-ASA)
Pharmacological Class Aminosalicylates (Anti-inflammatory agents)
Rx Status Prescription-only medicine
Key Forms Oral tablets/granules, Rectal suppositories/enemas
Origin Synthetic compound

Sulimax: Identity, Composition, and Pharmacological Class

Sulimax is a prescription-only medicine whose fundamental active component is Mesalazine, chemically known as 5-aminosalicylic acid (5-ASA). This compound is classified as an aminosalicylate anti-inflammatory agent. Mesalazine is a single-ingredient product of synthetic origin, belonging to the chemical family of salicylates. This composition is characterized by its delivery of the active therapeutic part directly, without the need for the body to cleave off the carrier molecules found in older analogues like Sulfasalazine.

Available Forms and Targeted Delivery Type

The medication is produced in several dosage forms, including oral tablets and granules for enteral delivery, along with rectal suppositories and enemas for direct localized administration. A key feature of these Mesalazine formulations is the use of modified-release technology. This pharmaceutical design is intended to allow the Mesalazine to be released at the inflamed mucosal surface, which limits systemic absorption and focuses the local anti-inflammatory action where it is required.

General Purpose: What does Sulimax Help to Relieve?

The general purpose of Sulimax is to provide localized anti-inflammatory action directly to the lining of the bowel. It achieves this by modulating the inflammatory cascade, specifically by interfering with the production of pro-inflammatory mediators such as prostaglandins and leukotrienes. By addressing these mechanisms, the medication intervenes to stabilize the inflammatory process. The drug is typically used to support chronic disease management and facilitate mucosal healing for individuals requiring targeted anti-inflammatory support in the gastrointestinal tract.

What side effects are possible with Sulimax?

Possible Side Effects and Safety Information

The safety profile of mesalazine (the active component of Sulimax) is structured by regulatory bodies based on documented adverse reactions and frequency classifications. Side effects are formally grouped according to the body system affected, known as System-Organ Classes (SOCs), which include effects on the Gastrointestinal System, Nervous System, Skin, Renal, and Cardiac systems.

Adverse reactions are classified by their documented frequency. Common reactions (occurring in 1 to 10 out of 100 patients) often include headache, abdominal pain, nausea, diarrhoea, and flatulence. Rare reactions (occurring in 1 to 10 out of 10,000 patients) include myocarditis and pericarditis, which are cardiac hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Official labeling documents specific serious adverse reactions. These include Acute Intolerance Syndrome, which may mimic an exacerbation of the underlying disease with symptoms like cramping, bloody diarrhoea, fever, and rash, often reported shortly after treatment initiation. Rare but life-threatening Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), and serious nephrotoxicity (e.g., interstitial nephritis, renal failure) are also documented in regulatory sources.

The medicine is officially contraindicated (should not be used) in patients with severe hepatic (liver) or severe renal (kidney) impairment. Caution is required when using the medicine concurrently with azathioprine or 6-mercaptopurine, as this combination may increase the risk of blood disorders (myelosuppression). Patients with pre-existing atopic dermatitis or atopic eczema are noted to be at a higher risk of more severe photosensitivity reactions.

Overdose and Emergency Response

Sulimax Overdose and when to seek help

Overdose Scope: Documented Findings

Due to the nature of the active ingredient in Sulimax, which is Mesalamine, clinical experience with acute, accidental overdose is limited. However, the compound is an aminosalicylate, structurally related to aspirin. Overdose may therefore involve signs of salicylate toxicity.

Potential Clinical Manifestations

Symptoms reported following high doses or overdose of mesalamine or related agents may affect several physiological systems. These can include: tinnitus (ringing in the ears), vertigo, headache, confusion, diarrhea, vomiting, and generalized drowsiness. Severe overexposure, particularly in vulnerable patients, can potentially lead to symptoms associated with acid-base disturbances and impaired renal function.

When to Seek Immediate Medical Help

Urgent medical attention is required immediately in any suspected overdose situation or if an individual takes more than the prescribed dosage of Sulimax. Contact emergency medical services, a poison control center, or report to an emergency room right away. This applies even if no immediate symptoms are apparent.

Emergency Actions

The management of mesalamine overdose is largely supportive, aiming to address any symptoms that develop. Since there is no specific antidote, prompt professional medical assessment is critical. Healthcare professionals will determine the necessary treatment, which may include observation, monitoring of kidney function, and correcting fluid or electrolyte imbalances.

Specific Risk Factors

Patients with pre-existing renal impairment may be at increased risk of adverse effects from cumulative exposure, but this is a general warning, not a specific overdose classification.

Therapeutic Uses of Sulimax

What Sulimax treats: main uses and benefits

The therapeutic domain of symptomatic relief is recognized in healthcare settings, and the medication is considered relevant for easing certain distressing symptoms. Sulimax is commonly used to help with symptoms related to physical discomfort and conditions involving episodic or fluctuating manifestations. The approach of using symptomatic support is common in healthcare, and this medication is relevant in contexts involving heightened systemic burden.

Key Areas of Use and Patient Benefit

Sulimax is applied in clinical settings that involve acute or unstable symptom patterns, such as during flare-ups or periods of heightened physiological activity. It is relevant for managing symptom clusters that may become intense or disruptive, including symptoms that relate to physical discomfort, systemic imbalance, or functional strain. The medication supports the patient during difficult episodes and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Supportive Symptomatic Assistance

Eligibility and Restrictions for Use

Who Can and Cannot Use Sulimax?

This section outlines the official population eligibility and exclusion criteria for Sulimax (Mesalazine/5-ASA) as defined by global regulatory bodies.


Official Contraindications

The medicine is absolutely contraindicated and must not be used in the following populations:

  • Patients with known hypersensitivity to Mesalazine (5-ASA) or to any other salicylate compound.
  • Individuals with severe renal impairment or severe hepatic impairment.

Age and Physiological Status Eligibility

Population Official Regulatory Status
Adults Established use for induction and maintenance therapy.
Pediatric Patients Use is formulation-dependent; generally approved only for children meeting specific minimum age (e.g., ge 5 years) or weight criteria.
Older Adults Use requires caution due to the higher likelihood of reduced organ function.
Pregnancy/Lactation Conditional use only; permitted when the treating physician determines the benefits clearly outweigh the potential risks.

Conditional Use and Restrictions

Use of Sulimax is restricted and requires careful monitoring in patients with mild to moderate renal or hepatic impairment, as well as in patients with a history of Sulfasalazine allergy or chronic lung conditions such as asthma. The treating physician must periodically evaluate organ function for these groups.

What should I know about interactions with other medicines?

Sulimax Interactions with other medicines and products

Sulimax (Sulpiride) interacts with several categories of medicinal products, primarily through pharmacodynamic effects that alter central nervous system (CNS) function and cardiac electrical activity, or through pharmacokinetic effects that reduce absorption.

Contraindicated and Not Recommended Combinations

Interaction Type Interacting Products/Category Mechanism & Constraint
Contraindicated Levodopa, Antiparkinsonian drugs (e.g., ropinirole) Reciprocal antagonism of effects; combined use is prohibited.
Not Recommended Alcohol, Alcohol-containing medicines Potentiation of CNS sedative effects; consumption must be avoided.
Not Recommended QTc-prolonging or Torsades de pointes inducing medicines (e.g., certain antiarrhythmics, neuroleptics, IV erythromycin, halofantrine, specific digitalis and antihypertensive agents) Increased risk of serious ventricular arrhythmias. Pre-existing electrolyte imbalance (especially hypokalemia) must be corrected.

Other Clinically Relevant Interactions

Concomitant use with CNS depressants (including narcotics, analgesics, and benzodiazepines) requires caution due to an additive risk of sedation. When combined with antihypertensive agents, there is an enhanced risk of postural hypotension due to additive effects.

Regarding the absorption of Sulimax, Antacids and Sucralfate are known to decrease its gastrointestinal uptake. To manage this interaction, Sulimax must be administered two hours before antacids or sucralfate.

Use with Lithium should be taken into account as it increases the risk of extrapyramidal effects, and discontinuation of both agents is advised at the first sign of neurotoxicity.

Mechanism of Action

How Sulimax Works

Interruption of Inflammatory Enzyme Pathways

The compound acts locally by inhibiting key enzymes in the Arachidonic Acid ( AA) cascade: Cyclooxygenase ( COX) and 5-Lipoxygenase (5-LOX). Inhibition of both enzyme systems reduces the synthesis of pro-inflammatory messengers, including Prostaglandins ( PGs) and the chemoattractant Leukotriene B4 ( LTB4). This reduction in chemical signaling decreases the synthesis of mediators associated with edema and lowers the accumulation of immune cells at the tissue site.

Modulation of Nuclear Signaling and Gene Expression

The compound also acts as an agonist for the PPARgamma nuclear receptor, engaging a mechanism that suppresses the transcription factor NF-kappa B. This genomic modulation reduces the transcription of genes synthesizing inflammatory cytokines ( TNF-alpha, IL-1), which alters the molecular basis of the immune response within the mucosa.

Anti-Oxidant Cellular Protection

Mesalazine possesses intrinsic antioxidant properties, enabling it to directly scavenge and neutralize Reactive Oxygen Species ( ROS) and free radicals released by activated cells. This non-enzymatic mechanism neutralizes species that cause oxidative damage, which influences the structural integrity of cells within the gut lining.

Dosage and Administration Information

Administration Guidelines: Sulimax

This section provides instructions for the use of Sulimax solution for injection, detailing the procedural steps for administration.


Administration Scope

Classification Instruction
Route of Administration Subcutaneous injection only (Do not administer intravenously or intramuscularly).
Official Dosing Rule The maximum daily dose is 60 units of insulin glargine and 20 mcg of lixisenatide, corresponding to 60 dose steps. Sulimax must not be used for total daily doses exceeding 60 dose steps.
Frequency and Timing Injected once a day and must be performed within one hour prior to a meal. It is preferable to administer it before the same meal every day.
Preparation Requirements Use as a solution in a pre-filled pen. Patients must be instructed to always use a new needle for each injection. Do not mix or dilute with any other products.
Age-Group Rules Elderly patients (over 65) can use Sulimax; the dose should be adjusted on an individual basis with close glucose monitoring. There is no relevant use documented in the paediatric population.
Missed-Dose Instructions If a dose is missed, it should be injected within the hour prior to the next meal.
Special Conditions Injection must be performed in the abdomen, deltoid, or thigh. The injection sites must be rotated within the same region from one injection to the next.

Resulting Procedural Structure

Official step sequence:

  • Inspect the pre-filled pen and attach a new, unused needle.
  • Select one of the approved injection sites: the abdomen, deltoid (upper arm), or thigh region.
  • Inject the individually determined dose subcutaneously once daily.
  • Ensure the injection occurs within one hour before the same meal each day.
  • Rotate the exact location of the injection within the chosen region to minimize risk of local tissue reactions.

Recent Clinical Evidence

The research evidence for Sulimax focuses on examining inflammatory states in the digestive tract, with findings describing group patterns observed in studies. This overview details the types of research conducted, the outcomes they measured, and areas where certainty remains low or evidence is limited.

Research for Ulcerative Colitis (UC)

The foundation of the evidence comes from short-term Randomized Controlled Trials (RCTs) that studied adults with active, mild-to-moderate UC. These trials measured clinical endpoints related to the change in symptoms and endoscopic endpoints related to mucosal healing. Findings describe patterns observed in these studies compared to placebo groups. Uncertainty remains regarding the differences between very high doses and moderate doses for measured clinical goals, as findings were mixed in some comparative studies.

Longer-term trials and observational studies were utilized to explore the maintenance of remission. Research monitored the frequency of episodic changes over many months, reporting that continued use of Mesalazine was observed to be associated with measured maintenance of remission status. For inflammation limited to the distal bowel (proctitis), localized formulations were specifically examined, and studies reported data showing patterns related to measured changes in local outcomes.

Evidence Gaps and Uncertainties

Evidence for other studied conditions is more limited. Scientific literature frequently describes the evidence for inducing and maintaining remission in Crohn's Disease as having low certainty, with inconsistent patterns observed across trials. Similarly, Mesalazine was observed in trials for Irritable Bowel Syndrome (IBS), but results from primary symptom endpoints were not consistently reported when compared to placebo.

Key research limitations include the fact that comparative evidence is lacking regarding the optimal dosing frequency for long-term remission, and data for certain groups, such as pediatric populations, remain insufficient. Furthermore, studies examining the role of Mesalazine in long-term outcomes related to potential malignancy in UC patients remain an area where certainty remains low, requiring further research. Results apply only to the populations studied and do not determine whether an individual will respond similarly.

Key Studies & References

  1. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
  2. Mesalamine for the Treatment of Crohn Disease (Systematic Review)
  3. Randomised clinical trial and meta‐analysis: mesalazine treatment in irritable bowel syndrome—effects on gastrointestinal symptoms
  4. Systematic review: safety of mesalazine in ulcerative colitis

Frequently Asked Questions (FAQ)

Common questions about Sulimax (FAQ)

Q: Has Sulimax been approved by the FDA, EMA, or other regulatory bodies?

A: According to regulatory documents, the product containing insulin glargine and lixisenatide has received approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals confirm its use for improving blood sugar control in adults with Type 2 diabetes mellitus.

Q: How does Sulimax work to treat the condition it is prescribed for?

A: Official product information describes Sulimax as a combination of two medicines. One is a long-acting insulin that helps regulate the body’s blood sugar levels. The other is a GLP-1 receptor agonist, which assists by stimulating the release of insulin and slowing down digestion to improve blood sugar control.

Q: Are there different forms (tablet, liquid, extended-release) of Sulimax available?

A: The product is officially supplied only as a solution that is administered via a disposable, pre-filled pen. It is not available in other formats such as tablets or extended-release capsules.

Q: What should I do if I accidentally take more Sulimax than prescribed?

A: Taking more than the prescribed amount can lead to a dangerously low blood sugar level, known as severe hypoglycemia, as well as low potassium (hypokalemia). Because of the serious risks, official regulatory documents typically instruct that immediate medical assistance should be sought in the event of an overdose.

Q: Is Sulimax designed to treat the root cause or just the symptoms?

A: The medicine is indicated to improve blood sugar control, which is a primary manifestation of Type 2 diabetes. It works by regulating the elevated glucose levels in the body. It is used in addition to diet and exercise, not as a replacement for these lifestyle measures.

Q: Is it important to take Sulimax at the exact same time every day?

A: Official prescribing information states the product is administered once a day. For consistent management of blood sugar, the product information indicates it is preferable for the administration to occur within one hour before the same meal every day.

Q: What is the chemical or active ingredient name of Sulimax?

A: Sulimax is a combination medication containing two active chemical compounds. These are insulin glargine (a long-acting insulin) and lixisenatide (a GLP-1 receptor agonist).

Q: What is the official recommended action if Sulimax causes skin reactions?

A: Regulatory information notes that local skin reactions at the injection site can occur. To help minimize the risk of problems like skin thickening, the product label describes rotating the exact site of injection within the approved regions (abdomen, thigh, or upper arm) for each dose.

Q: What is the main medical purpose of Sulimax?

A: The main medical purpose of Sulimax is to help improve blood sugar control. It is indicated specifically for adults who have Type 2 diabetes mellitus. It is used in combination with dietary changes and increased physical activity.

Q: How quickly should I expect Sulimax to start working?

A: Official data on pharmacokinetics indicates that the product typically begins to lower blood glucose levels approximately two hours after the injection. It is formulated to provide a steady and prolonged effect over a 24-hour period.

Q: What are the most common side effects reported for Sulimax?

A: According to the regulatory documents, common side effects reported in studies include low blood sugar (hypoglycemia), nausea, diarrhea, and headache. Upper respiratory tract infection is also frequently reported.

Q: Does Sulimax cause any noticeable changes in appetite or weight?

A: Weight gain is a potential adverse reaction associated with the insulin component of the medicine. Additionally, common side effects like nausea and diarrhea may indirectly affect appetite.

Q: Is it safe to drink alcohol while taking Sulimax?

A: Official patient information states that alcohol consumption should be avoided. This is because alcohol can increase the risk of developing dangerously low blood sugar (hypoglycemia) and interfere with the goal of blood sugar management.

Q: Can Sulimax be taken with common over-the-counter pain relievers?

A: Official drug interaction information notes that the medicine can affect the absorption of certain oral medications, including oral acetaminophen (a common pain reliever). The product information states that the intake of such oral medications should be timed to avoid interaction, typically recommending administration 1 hour before or 11 hours after the injection.

Q: What types of interactions are listed for Sulimax and other medicines?

A: The product has two main types of interactions listed in official documents. One is with oral medicines whose absorption is affected by slowed digestion. The other is with various drugs, such as corticosteroids and diuretics, that can impact blood glucose levels.

Q: What does official guidance say about using Sulimax during pregnancy?

A: Official guidance states that it is not known if the product will harm an unborn baby. Prescribing information indicates that the drug should only be used during pregnancy if the potential benefit to the patient is judged to outweigh the potential risk to the fetus.

Q: What are the contraindications or warnings for Sulimax listed on the official label?

A: The official label contraindicates its use during episodes of low blood sugar (hypoglycemia) or if a patient has a severe hypersensitivity to the ingredients. Warnings address serious risks such as acute pancreatitis, kidney injury, and the need for safe pen use.

Q: Is it normal to feel tired or dizzy after starting Sulimax?

A: Dizziness and fatigue are listed as common reported adverse reactions. Additionally, symptoms like dizziness or confusion can be signs of the most common side effect, hypoglycemia (low blood sugar).

Q: Do side effects from Sulimax usually lessen over time?

A: Some side effects, especially gastrointestinal issues like nausea, may decrease as treatment continues. However, official prescribing information notes that patients should discuss any bothersome or persistent side effect with their healthcare provider.

Q: Can Sulimax affect my ability to drive or operate machinery?

A: Because the medicine can cause hypoglycemia (low blood sugar), which can impair concentration, the product label cautions that if patients are experiencing symptoms of low blood sugar, the ability to drive or operate heavy machinery may be impaired, and these activities should be avoided.

Q: Where can I find reliable, official information about Sulimax clinical trials?

A: Reliable information on the clinical trials and studies used for approval is publicly available through official regulatory sources. These include the FDA Approval Package and public registries such as ClinicalTrials.gov.

Q: Are there any specific foods or supplements that interact with Sulimax?

A: While specific food interactions are not generally listed, the drug's components may affect the absorption of other oral medicines, including supplements. It is noted that changes in diet or meal patterns can affect blood sugar control.

Q: Does Sulimax contain any ingredients considered to be steroids?

A: According to the official composition, the active ingredients are insulin glargine and lixisenatide. It does not contain any ingredients classified as corticosteroids (steroids).

Q: What are the signs of a serious allergic reaction to Sulimax?

A: Official warnings state that signs of a serious allergic reaction may include swelling of the face, lips, tongue, or throat, or trouble breathing. Other serious signs are fainting, a very rapid heartbeat, or a severe, widespread rash.

Q: Can people with liver function issues use Sulimax?

A: Patients who have hepatic impairment (liver problems) may require closer monitoring of their blood glucose levels. The prescribing information does not list all liver conditions as a contraindication, but cautions are noted.

Q: What should I do if the side effects of Sulimax are bothersome?

A: Official regulatory patient counseling information states that any side effect that is bothersome, persistent, or does not go away should be brought to the attention of a healthcare provider.

Q: Is Sulimax the type of drug that needs to build up in the system?

A: The medication is used for continuous, daily blood sugar management. Its insulin component provides a prolonged, steady action over 24 hours after each daily dose, helping to maintain stable blood sugar control.

Q: Are there any long-term health risks associated with taking Sulimax?

A: Official warnings address potential serious long-term risks, including acute pancreatitis and gallbladder disease. There is also a possibility of developing antibodies to the active ingredients over time.

Q: Can Sulimax affect blood pressure or heart rate?

A: Rapid heartbeat is one of the signs of a serious allergic reaction that warrants immediate attention. The medicine may also increase the risk of fluid retention, which can be a concern for certain heart conditions when used alongside other diabetes drugs.

Q: Is Sulimax safe to take with my daily vitamin regimen?

A: The GLP-1 component of the medicine can slow down stomach emptying, which may potentially affect the way the body absorbs orally administered medicines and supplements. It is generally advised that any oral vitamin or supplement regimen should be discussed with a healthcare provider.

Q: Is Sulimax a controlled drug?

A: No, according to official drug scheduling information, the product is not classified as a federally controlled substance.

Q: Who cannot use Sulimax due to pre-existing conditions?

A: Official warnings state that the medicine is not recommended for patients with a personal history of acute pancreatitis. It is also not recommended for patients with end-stage kidney disease or severe stomach problems, such as gastroparesis.

Q: Does official research show Sulimax interacting with hormonal birth control?

A: Official drug interaction studies indicate that the lixisenatide component can slow digestion, which may decrease the effectiveness of oral contraceptives. Product labeling specifies that oral birth control pills should be taken at least 1 hour before or 11 hours after the injection to minimize the risk of decreased effectiveness.

Q: Is it true that Sulimax can affect the results of certain lab tests?

A: The medicine is associated with risks such as hypokalemia (low potassium) and acute kidney injury. Because of this, the standard laboratory monitoring required for these conditions would be reflected in blood test results.

Q: What does the research say about Sulimax and potential mental health effects?

A: The research and safety information list mental or emotional state changes, such as anxiety, irritability, or confusion, as possible symptoms of hypoglycemia (low blood sugar), which is a common side effect of the medicine.

Q: Can people with kidney disease safely take Sulimax?

A: Patients with mild-to-moderate kidney impairment may require careful monitoring of their kidney function while using the medication. However, official guidance states that the medicine is not recommended for patients with end-stage renal disease (ESRD).

Q: What are the official storage instructions for Sulimax?

A: Official storage instructions indicate that unopened pens should be kept in the refrigerator and should not be frozen. Once the pen is in use, it must be stored at room temperature (below 77°F or 25°C) and discarded after 28 days.

Q: How is the safety profile of Sulimax generally described in medical literature?

A: The safety profile of Sulimax is generally described in regulatory and medical literature as being consistent with the known safety information for its individual active components, insulin glargine and lixisenatide.

Q: Are there any post-marketing studies on Sulimax that are publicly available?

A: Yes, official safety data and post-marketing surveillance reports are continually reviewed by regulatory bodies. This information, along with results from clinical studies, is generally available to the public through regulatory databases.

Q: Does Sulimax interact with cold and flu remedies that contain decongestants?

A: Certain cold and flu remedies, particularly those containing decongestants, can impact a patient’s blood sugar levels. Official warnings indicate that increased monitoring of blood glucose may be necessary when taking any other medication that is known to affect blood sugar control.

Q: Are there official warnings about combining Sulimax with other mental health medications?

A: Official warnings are provided regarding combining the medicine with certain drugs, such as PPAR-gamma agonists, which are sometimes prescribed in mental health protocols. These combinations can increase the risk of fluid retention and heart failure.

Q: Why is a prescription required to get Sulimax?

A: Sulimax is classified as a prescription-only medicine because of the need for professional medical supervision to ensure safe and effective use. This is due to potential serious risks like severe hypoglycemia (low blood sugar) that require precise dosing and monitoring.

Q: Can people with diabetes safely use Sulimax?

A: The medicine is officially indicated for improving blood sugar control in adults with Type 2 diabetes mellitus. It is not used for the treatment of Type 1 diabetes or for diabetic ketoacidosis.

How should Sulimax be stored and disposed of?

Storage and Disposal Requirements for Mesalazine (Sulimax)

Official regulatory guidance dictates specific storage and handling requirements for mesalazine, which vary by dosage form.

Storage Conditions

Oral tablets and capsules must be kept in the original, tightly closed container to protect them from moisture and stored below 25 C. Rectal enemas must be protected from light and stored below 30 C. Rectal suppositories may be refrigerated or stored below 25 C and must be kept away from surfaces that can be stained.

Stability and Handling

All forms must be kept out of the reach of children. For rectal enemas, any unused units must be discarded after 14 days of opening the foil wrap. Disposal of unused or expired product must follow local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulimax found in:

A-Z Index: